Though lung cancer is a complicated disease, scientists have begun to unravel its complexities, giving new hope to patients.

Like the human body or an urban centre, lung cancer is a knot of intricacies. As such, Toronto, a city of many histories, offers the perfect setting for the 19th World Conference on Lung Cancer (WCLC), an assembly of experts from over 100 countries.

By bringing together international clinicians, researchers, scientists and patient advocates, the many sides of lung cancer will be addressed from cross-disciplinary perspectives. Only by sharing this knowledge can we put the latest discoveries into context, make connections and learn what this means for patients.

It’s an incredibly exciting time for lung cancer research and treatment, both in terms of diagnostics and drug development. New information is empowering us to help lung cancer patients like never before.
Dr. William Pao, M.D., Ph.D, Head of Roche Pharma Research and Early Development

Our contribution

A multifaceted disease needs a multipronged approach. At the WCLC from 23 to 26 September, we will present our newest findings in the area of lung cancer care. We will share both pharmaceutical and diagnostic data on biomarkers, personalised healthcare and immunotherapies. We will provide updates on our ongoing research, clinical trials and the investigational medications in our pipeline.

At the WCLC, the world unites to untangle this complex disease. And we’re proud to be a part of that. You can find background information on some of these topics by clicking the stories below.

Tags: Innovation, Oncology